UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

SCHEDULE 13G

 

Under the Securities Exchange Act of 1934

(Amendment No. 1 Exit Filing)*

 

 

DAY ONE BIOPHARMACEUTICALS, INC.

(Name of Issuer)

 

Common Stock

(Title of Class of Securities)

 

23954D109

(CUSIP Number)

 

June 21, 2022

(Date of Event Which Requires Filing of this Statement)

 

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 

☐ Rule 13d-1(b)

☐ Rule 13d-1(c)

☒ Rule 13d-1(d)

 

*	The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

 

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (the “Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

CUSIP No. 23954D109

 

(1)			Names of reporting persons   Takeda Pharmaceutical Company Limited
(2)			Check the appropriate box if a member of a group (see instructions) (a) ☐ (b) ☐
(3)			SEC use only
(4)			Citizenship or place of organization   Japan
Number of shares beneficially owned by each reporting person with:						(5)		Sole voting power   0
						(6)		Shared voting power   0
						(7)		Sole dispositive power   0
						(8)		Shared dispositive power   0
(9)				Aggregate amount beneficially owned by each reporting person   0
(10)				Check if the aggregate amount in Row (9) excludes certain shares (see instructions)   ☐
(11)				Percent of class represented by amount in Row (9)   0% (1)
(12)				Type of reporting person (see instructions)   CO

(1) Based on 73,549,526 shares of the Issuer’s Common Stock issued and outstanding as of November 2, 2022, as reported in the Issuer’s Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on November 7, 2022.

 

 

CUSIP No. 23954D109

 

(1)			Names of reporting persons   Takeda Ventures, Inc.
(2)			Check the appropriate box if a member of a group (see instructions) (a) ☐ (b) ☐
(3)			SEC use only
(4)			Citizenship or place of organization   USA
Number of shares beneficially owned by each reporting person with:						(5)		Sole voting power   0
						(6)		Shared voting power   0(1)
						(7)		Sole dispositive power   0
						(8)		Shared dispositive power   0(1)
(9)				Aggregate amount beneficially owned by each reporting person   0(1)
(10)				Check if the aggregate amount in Row (9) excludes certain shares (see instructions)   ☐
(11)				Percent of class represented by amount in Row (9)   0% (2)
(12)				Type of reporting person (see instructions)   CO

(1) TVI is a direct, wholly owned subsidiary of Takeda Pharmaceuticals U.S.A Inc. (“TPUSA”), which is owned directly by both Takeda Pharmaceutical Company Limited (72.7%) and Takeda Pharmaceuticals International AG (27.30%). Takeda Pharmaceuticals International AG is a direct, wholly owned subsidiary of Takeda Pharmaceutical Company Limited.

 

(2) Based on 73,549,526 shares of the Issuer’s Common Stock issued and outstanding as of November 2, 2022, as reported in the Issuer’s Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on November 7, 2022.

 

 

Explanatory Note:

 

This Amendment No. 1 (this “Amendment”) amends, in its entirety, the statement on Schedule 13G originally filed on January 14, 2022 by the Reporting Persons in relation to the common stock, par value $0.0001 per share (the “Common Stock”) of Day One Biopharmaceuticals, Inc., a Delaware corporation (the “Issuer”). This Amendment is being filed (i) to reflect an internal reorganization effected by the Reporting Persons on July 1, 2022 whereby Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceuticals U.S.A., Inc. (“TPUSA”), distributed the shares of the Issuer’s Common Stock owned by it to TPUSA, which immediately thereafter contributed such shares of the Issuer’s Common Stock to Takeda Ventures, Inc. (“TVI”), a wholly owned subsidiary of TPUSA, and (ii) to disclose that the Reporting Persons have ceased to be the beneficial owners of more than five percent of the outstanding shares of Common Stock of the Issuer. This Amendment is the final amendment to the Schedule 13G and constitutes an exit filing for each Reporting Person.

 

Item 1(a)

Name of issuer:

 

Day One Biopharmaceuticals, Inc.

 

Item 1(b)

Address of issuer’s principal executive offices

  

2000 Sierra Point Parkway, Suite 501

 

Brisbane, California 94005

 

Item 2(a)

Name of person filing:

 

Takeda Pharmaceutical Company Limited

 

Takeda Ventures, Inc.

 

Item 2(b)

Address of principal business office or, if none, residence:

 

Takeda Pharmaceutical Company Limited – 1-1, Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo M0 103-8668, Japan

 

Takeda Ventures, Inc. – 9625 Towne Centre Drive, San Diego, California 92121, USA

 

Item 2(c)

Citizenship:

 

Takeda Pharmaceutical Company Limited – Japan

 

Takeda Ventures, Inc. – USA

 

Item 2(d)

Title of class of securities:

 

Common Stock

 

Item 2(e)

CUSIP No.:

 

23954D109

 

Item 3.

If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

 

Not applicable.

 

 

Item 4.

Ownership

 

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

 

(a) Amount beneficially owned: See the responses in Row 9 on the attached cover pages.

 

(b) Percent of class: See the responses in Row 11 on the attached cover pages.

 

(c) Number of shares as to which the person has:

 

(i) Sole power to vote or to direct the vote: See the responses in Row 5 on the attached cover pages.

 

(ii) Shared power to vote or to direct the vote: See the responses in Row 6 on the attached cover pages.

 

(iii) Sole power to dispose or to direct the disposition of: See the responses in Row 7 on the attached cover pages.

 

(iv) Shared power to dispose or to direct the disposition of: See the responses in Row 8 on the attached cover pages.

 

The percentages used herein and in this Item 4 are calculated based on 73,549,526 shares of the Issuer’s Common Stock issued and outstanding as of November 2, 2022, as reported in the Issuer’s Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on November 7, 2022.

 

Item 5.

Ownership of 5 Percent or Less of a Class.

 

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☒.

 

Item 6.

Ownership of More than 5 Percent on Behalf of Another Person.

 

Not applicable.

 

Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

 

See Exhibit 99.1.

 

Item 8.

Identification and Classification of Members of the Group.

 

Not applicable.

 

Item 9.

Notice of Dissolution of Group.

 

Not applicable.

 

Item 10.

Certifications

 

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

 

 

Signatures

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

Dated: February 3, 2023

	TAKEDA PHARMACEUTICAL COMPANY LIMITED
	By	/s/ Yoshihiro Nakagawa
	Name:	Yoshihiro Nakagawa
	Title:	Global General Counsel

 

	TAKEDA VENTURES, INC.
	By	/s/ Michael Martin
	Name:	Michael Martin
	Title:	President

 

 

INDEX TO EXHIBITS

 

Exhibit 99.1	Identification of the subsidiary which acquired the security being reported on by the parent holding company
Exhibit 99.2	Joint Filing Agreement

 

 

 

Exhibit 99.1

 

Identification of the subsidiary which acquired the security being reported on by the parent holding company.

 

Takeda Pharmaceutical Company Limited’s beneficial ownership of the reported securities is comprised of zero shares of Common Stock held by Takeda Ventures, Inc., a wholly owned indirect subsidiary of Takeda Pharmaceutical Company Limited. Takeda Ventures, Inc. is owned directly by Takeda Pharmaceuticals U.S.A., Inc., which is owned directly by both Takeda Pharmaceutical Company Limited (72.7%) and Takeda Pharmaceuticals International AG (27.30%). Takeda Pharmaceuticals International AG is a wholly owned direct subsidiary of Takeda Pharmaceutical Company Limited.

 

 

 

Exhibit 99.2

 

JOINT FILING AGREEMENT

 

In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, the undersigned agree to the joint filing of a Statement on Schedule 13G (including any and all amendments thereto) with respect to the Common Stock of Day One Biopharmaceuticals, Inc. and further agree to the filing of this agreement as an Exhibit thereto. In addition, each party to this Agreement expressly authorizes each other party to this Agreement to file on its behalf any and all amendments to such Statement on Schedule 13G.

 

Dated: February 3, 2023

	TAKEDA PHARMACEUTICAL COMPANY LIMITED
	By	/s/ Yoshihiro Nakagawa
	Name:	Yoshihiro Nakagawa
	Title:	Global General Counsel

 

	TAKEDA VENTURES, INC.
	By	/s/ Michael Martin
	Name:	Michael Martin
	Title:	President